Project Grant HT94252510094
Award Date
7/1/25
Completion Date
6/30/28
Dollars Obligated
$1.2M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
This $1,171,770.00 Project Grant, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research at Baylor College of Medicine to investigate brain representations of language in children with tuberous sclerosis complex. The award period is from July 1, 2024 to June 30, 2027. Tuberous sclerosis complex is a rare genetic disorder that can cause neurological symptoms, making this a critical area of medical research. The findings...
The Defense Health Agency awarded a $802,500 Project Grant (CFDA 12.420 - Military Medical Research and Development) to Baylor College of Medicine to conduct preclinical gene therapy studies in a mouse model of TSC2, a genetic disorder. The award period is from May 1, 2025 to April 30, 2028. As a prime recipient and collaborative research partner, Baylor College of Medicine has extensive expertise across various medical disciplines, including genomics, neuroscience, and rare genetic disorders....
This $793,572 federal Project Grant award was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award supports a novel translational research project investigating the pathophysiology of tuberous sclerosis complex (TSC) at Brigham & Women's Hospital Inc., a prominent academic medical center in Boston, Massachusetts. The research aims to advance the understanding of the underlying mechanisms driving TSC, with the...
The Trustees of Columbia University in the City of New York will research autophagy induction as a novel therapeutic strategy for tuberous sclerosis complex-associated cognitive and autistic social deficits under a $810,000 Project Grant from the Department of the Army Medical Command. The grant was awarded on September 1, 2022 and runs through August 31, 2025. The funding supports research that aligns with the Military Medical Research and Development program (CFDA 12.420) to investigate...
The Washington University received a $236,250 project grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant funding supports research from July 1, 2021 to June 30, 2023 to study the role of blood-brain barrier dysfunction in epilepsy associated with tuberous sclerosis complex. The Military Medical Research and Development program aims to transform military and public health through innovative biomedical...
The Department of the Army Medical Command awarded a $1,715,894 project grant to Brigham & Women's Hospital Inc. under the Military Medical Research and Development program. The grant will fund research from August 1, 2022 to July 31, 2025 to target tuberous sclerosis complex (TSC) by developing mTORC1-specific bi-steric inhibitors. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming military and...
The Children's Hospital Corporation, doing business as Boston Children's Hospital, was awarded a $796,500 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program. The grant will fund research from July 2021 through June 2024 to investigate the contribution of rapamycin-insensitive processes to neurological symptoms in tuberous sclerosis complex. The Military Medical Research and Development program aims to advance biomedical...
This federal Project Grant award from the Department of the Army Medical Command (CFDA 12.420 - Military Medical Research and Development) provides $361,931 to the University of California, San Diego (UCSD) to investigate microglia dysfunction in MEF2C deficiency autism spectrum disorder, with the goal of discovering new targeted therapies. The award period runs from September 30, 2024 to September 29, 2027. UCSD, a leading academic research institution, will leverage its expertise in...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $822,501.00 to The Trustees of Columbia University in the City of New York to conduct research on "Restoring Gabaergic Inhibition as a Potential Therapy for TSC-Associated Neurocognitive Impairment." The research, taking place from May 1, 2025 to April 30, 2028, aims to investigate innovative therapeutic approaches for addressing...
The Department of the Army Medical Command awarded $1.59 million to Children's Hospital Medical Center under the Military Medical Research and Development program (CFDA 12.420) for the period of June 15, 2022 to June 14, 2025. The project aims to investigate whether there is a point of convergence between congenital heart disease and autism by supporting basic, applied, and advanced biomedical research to transform military and public health care. The Military Medical Research and Development...